metformin has been researched along with Nutritional Disorders in 1 studies
Metformin: A biguanide hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus not responding to dietary modification. Metformin improves glycemic control by improving insulin sensitivity and decreasing intestinal absorption of glucose. (From Martindale, The Extra Pharmacopoeia, 30th ed, p289)
metformin : A member of the class of guanidines that is biguanide the carrying two methyl substituents at position 1.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The antidiabetic drug metformin has been proposed to affect non-alcoholic fatty liver disease (NAFLD) through its effects on intestinal microbiota and barrier function." | 7.91 | Metformin attenuates the onset of non-alcoholic fatty liver disease and affects intestinal microbiota and barrier in small intestine. ( Baumann, A; Bergheim, I; Brandt, A; Camarinha-Silva, A; Hernández-Arriaga, A; Jin, CJ; Kehm, R; Nier, A; Sánchez, V, 2019) |
| "The antidiabetic drug metformin has been proposed to affect non-alcoholic fatty liver disease (NAFLD) through its effects on intestinal microbiota and barrier function." | 3.91 | Metformin attenuates the onset of non-alcoholic fatty liver disease and affects intestinal microbiota and barrier in small intestine. ( Baumann, A; Bergheim, I; Brandt, A; Camarinha-Silva, A; Hernández-Arriaga, A; Jin, CJ; Kehm, R; Nier, A; Sánchez, V, 2019) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Brandt, A | 1 |
| Hernández-Arriaga, A | 1 |
| Kehm, R | 1 |
| Sánchez, V | 1 |
| Jin, CJ | 1 |
| Nier, A | 1 |
| Baumann, A | 1 |
| Camarinha-Silva, A | 1 |
| Bergheim, I | 1 |
1 other study available for metformin and Nutritional Disorders
| Article | Year |
|---|---|
Metformin attenuates the onset of non-alcoholic fatty liver disease and affects intestinal microbiota and barrier in small intestine.
Topics: Animals; Biomarkers; Disease Models, Animal; Gastrointestinal Microbiome; Hypoglycemic Agents; Intes | 2019 |